mucosal exposure is or vagina, swollen neck Increase in IgM/IgGtitres between generally moderate. The or face, conjunctivitis or acute and convalescent specimens) antiviral drug ribavirin seems subconjunctival OR is a suspected case with to be an effective treatment bleeding, spontaneous laboratory suggestive evidence of for Lassa fever if given early abortion, petechial or Lassa virus infection by (IgM on in the course of clinical hemorrhagic rash, new positive result on patient's first illness.The disease has a onset of tinnitus or specimen). gradual onset of fever with altered hearing, " malaise, anorexia, headache, persistent hypotension, chest or retrosternal pain, elevated AST or ALT sore throat, myalgia, OR 2. at least two major arthralgia, lumbosacral pain, signs or symptoms; AND dizziness, erythemic or having relevant exudative pharynx, nausea, epidemiological vomiting, epigastric, exposure (known contact abdominal pain, tenderness, to a person suspected, diarrhoea, morbilliform, probably or confirmed to maculopapular or petechial have lassa fever or have rash in fair-skinned people travelled to an endemic only, dry cough, no jaundice, area in the past 21 days). edema, swelling of the face, and neck specific, bleeding (conjunctival injection or subconjunctival hemorrhage, facial flushing, hematemesis, melena, hematochezia, metrorrhagia, petechiae, epistaxis, bleeding from the gums and venepuncture sites, vaginal bleeding, hemoptysis or hematuria infrequent), mild-to moderate thrombocytopenia, hypotension, shock, moderate leukopenia, later leukocytosis, increased AST, ALT and AST> ALT, lactate level greater than 36 mg/dL, proteinuria common, spontaneous abortion,
mucosal exposure is generally moderate. The antiviral drug ribavirin seems to be an effective treatment for Lassa fever if given early on in the course of clinical illness.The disease has a gradual onset of fever with malaise, anorexia, headache, chest or retrosternal pain, sore throat, myalgia, arthralgia, lumbosacral pain, dizziness, erythemic or exudative pharynx, nausea, vomiting, epigastric, abdominal pain, tenderness, diarrhoea, morbilliform, maculopapular or petechial rash in fair-skinned people only, dry cough, no jaundice, edema, swelling of the face, and neck specific, bleeding (conjunctival injection or subconjunctival hemorrhage, facial flushing, hematemesis, melena, hematochezia, metrorrhagia, petechiae, epistaxis, bleeding from the gums and venepuncture sites, vaginal bleeding, hemoptysis or hematuria infrequent), mild-to moderate thrombocytopenia, hypotension, shock, moderate leukopenia, later leukocytosis, increased AST, ALT and AST> ALT, lactate level greater than 36 mg/dL, proteinuria common, spontaneous abortion, or vagina, swollen neck or face, conjunctivitis or subconjunctival bleeding, spontaneous abortion, petechial or hemorrhagic rash, new onset of tinnitus or altered hearing, persistent hypotension, elevated AST or ALT OR 2. at least two major signs or symptoms; AND having relevant epidemiological exposure (known contact to a person suspected, probably or confirmed to have lassa fever or have travelled to an endemic area in the past 21 days). Increase in IgM/IgGtitres between acute and convalescent specimens) OR is a suspected case with laboratory suggestive evidence of Lassa virus infection by (IgM positive result on patient's first specimen). "
Appendix_C_NMC_case_definitions.docx